Triterpenoid Therapeutics
A biotechnology company developing brain‑penetrant synthetic triterpenoid small molecules that simultaneously inhibit inflammatory signaling (NLRP3 inflammasome) and modulate the Integrated Stress Response (ISR). The organization focuses on preclinical development of orally bioavailable compounds with demonstrated blood–brain barrier penetration and activity in neurodegenerative and brain cancer models, and maintains a pipeline of fluorinated analogs and patent filings.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Methods and compositions for inhibiting the NLRP3 inflammasome and/or LON protease
US-12370202-B2
View Details
Methods and compositions for inhibiting the NLRP3 inflammasome and/or LON protease
US-12370202-B2
View DetailsProducts
Lead oral brain‑penetrant triterpenoid (lead compound)
A fourth‑generation synthetic triterpenoid small molecule designed for oral delivery and CNS penetration with preclinical evidence of high potency, NLRP3 inhibition, ISR modulation, neuroprotection, and anti‑tumor activity in glioblastoma models.
Pipeline of fluorinated triterpenoid analogs
A series of patent‑pending fluorinated analogs intended to enhance brain penetration, selectivity, and safety while retaining oral bioavailability.
Lead oral brain‑penetrant triterpenoid (lead compound)
A fourth‑generation synthetic triterpenoid small molecule designed for oral delivery and CNS penetration with preclinical evidence of high potency, NLRP3 inhibition, ISR modulation, neuroprotection, and anti‑tumor activity in glioblastoma models.
Pipeline of fluorinated triterpenoid analogs
A series of patent‑pending fluorinated analogs intended to enhance brain penetration, selectivity, and safety while retaining oral bioavailability.
Expertise Areas
- Small‑molecule medicinal chemistry
- Brain‑penetrant drug development
- NLRP3 inflammasome biology
- Integrated Stress Response (ISR) modulation
Key Technologies
- Synthetic triterpenoid scaffold chemistry
- Blood–brain barrier penetration assessment
- NLRP3 inflammasome inhibition assays
- Integrated Stress Response pathway assays
News & Updates
Peer‑reviewed article reporting reduction in amyloid β in AD model mice associated with a NRF2 inducer compound.
Publication describing binding to GRP78/BiP and induction of unfolded protein response–mediated apoptosis in myeloma models.
Company announced issuance of a U.S. patent covering methods and compositions for inhibiting the NLRP3 inflammasome.
Peer‑reviewed article reporting reduction in amyloid β in AD model mice associated with a NRF2 inducer compound.
Publication describing binding to GRP78/BiP and induction of unfolded protein response–mediated apoptosis in myeloma models.
Company announced issuance of a U.S. patent covering methods and compositions for inhibiting the NLRP3 inflammasome.